EMA gives Hansa priority to develop novel enzyme

Swedish biotech firm Hansa Medical (STO: HMED) has been accepted onto the European Medicines Agency’s Priority Medicines (PRIME) scheme for lead candidate IdeS, an enzyme being developed to facilitate successful kidney transplantation.

The scheme offers enhanced interaction with companies to accelerate the clinical development and regulation process. Of the 96 PRIME applications received by the EMA thus far, 71 have received approval.

Chief executive Göran Arvidson said: “The granting of PRIME access by the EMA allows us to continue to accelerate the development of IdeS.”